Pliant Therapeutics (PLRX) Net Income towards Common Stockholders (2019 - 2026)

Pliant Therapeutics (PLRX) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$57.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 4.32% year-over-year to -$57.3 million; the TTM figure through Mar 2026 stood at -$187.7 million (up 21.15% YoY), while the FY2025 annual figure was -$374.5 million, up 12.27% from the prior year.
• Net Income towards Common Stockholders retreated to -$57.3 million in Q1 2026 per PLRX's latest filing, from -$15.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$15.0 million in Q4 2025 and bottomed at -$86.3 million in Q2 2025.
• Historically, Net Income towards Common Stockholders has averaged -$46.2 million across 5 years, with a median of -$41.5 million in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 79.36% — and 2025, when it soared 72.71%.
• Pliant Therapeutics' Net Income towards Common Stockholders stood at -$35.1 million in 2022, then tumbled by 79.36% to -$62.9 million in 2023, then rose by 12.5% to -$55.0 million in 2024, then jumped by 72.71% to -$15.0 million in 2025, then tumbled by 281.73% to -$57.3 million in 2026.
• Business Quant data shows PLRX's Net Income towards Common Stockholders at -$57.3 million in Q1 2026, -$15.0 million in Q4 2025, and -$29.0 million in Q3 2025.